Notes on Tumor Suppressors, Oncogenes, Epigenetics, and Therapeutic Implications
Course Announcements
Final project: check-in due Monday. Email or Canvas with your chosen scientist and the required information: who they were, their contribution, and how they qualify as underrepresented in STEM. Details are on Canvas.
Exam #3: next Wednesday at the usual time; topics include oncogenes, tumor suppressor genes, and what was covered on Monday (angiogenesis and metastasis).
Final project due: one week after exam #3, on Wednesday the 20th.
Final exam: cumulative, on Friday, August 22; course completion.
Quick pause reminder: any questions about tumor suppressors before moving on.
Next topic preview: after completing tumor suppressors, Monday will cover sustained angiogenesis and metastasis, and possible therapeutics related to these hallmarks.
Key Concepts: Hallmarks of Cancer and Overall Framework
Hallmarks (conceptual framework):
Self-sufficiency in growth signals (oncogenes)
Insensitivity to anti-growth signals (tumor suppressor genes)
Evading apoptosis (block of programmed cell death)
Limitless replicative potential (telomerase reexpression in many cancers)
Sustained angiogenesis
Invasion and metastasis
Evasion of immune responses (not elaborated deeply here)
Other alterations can contribute to these hallmarks; not all changes are due to mutations—epigenetic changes can play a role.
Reiterated theme: cancers evolve through multiple, overlapping pathways; mutating a single gene often isn’t sufficient due to redundancy in inhibitory signaling and network complexity.
Cancer progression often involves stepwise, ordered mutations, especially evident in colon cancer (APC → KRAS → SMAD4 → TP53) leading from normal mucosa to adenoma to carcinoma and metastasis.
Epigenetics as a non-genetic mechanism: changes in chromatin structure and DNA methylation can alter gene expression without changing DNA sequence; these changes contribute to cancer initiation and progression and can interact with genetic mutations.
Diagnostic and research tools: DNA microarrays can compare RNA expression between tumor and normal tissue to infer upregulated vs. downregulated genes and potential epigenetic regulation.
Therapeutic approach in modern oncology increasingly focuses on targeting altered pathways and exploiting tumor-specific dependencies; personalized medicine aims to tailor therapy based on an individual tumor’s mutation/epigenetic profile.
TGF-β/SMAD Signaling and Tumor Suppressor Roles
TGF-β is a secreted cytokine/growth factor with inhibitory effects on growth; paradoxically named transforming growth factor-β due to historical context (immunosuppressive signals).
In cancer, TGF-β can suppress the immune response or inhibit growth of nearby cells, providing a growth advantage to cancer cells when the pathway is mutated.
Mutations and alterations in TGF-β/SMAD signaling are common in cancers:
TGF-β receptor mutations are found in colon and stomach cancers.
SMAD transcription factors downstream of TGF-β are mutated in about \approx 50\% of pancreatic cancers and about \approx 30\% of colon cancers.
Consequences: downstream targets include CDK inhibitors (e.g., p21). Thus, signaling redundancy exists: multiple pathways can converge on the same outcome (cell cycle inhibition or promotion).
Redundancy explains why several tumor suppressor pathways must be inactivated to overcome growth control.
Key points to remember for exams:
p21 is a CDK inhibitor in the RB pathway; inactivation of this pathway promotes cell cycle entry.
Multiple tumor suppressors converge on preventing cell cycle progression; mutating more than one pathway provides a selective advantage.
CDKN2A Locus: p16INK4a and ARF (two proteins from one gene)
CDKN2A encodes two distinct proteins via alternative reading frames: p16INK4a and ARF (p14ARF in humans).
Two reading frames, two functions:
p16INK4a (CDK inhibitor): inhibits the CDK4/6–cyclin complex; prevents phosphorylation of RB; maintains RB in an active, growth-suppressive state; blocks cell cycle progression.
ARF (alternative reading frame): binds MDM2, preventing MDM2 from targeting p53 for degradation; stabilizes and activates p53, enabling p53-dependent tumor suppression.
Conceptual relationship: ARF is a negative regulator of a negative regulator (MDM2), which makes ARF a positive regulator of p53; p16 is a negative regulator of the RB pathway via CDK inhibition.
Implication of dual outputs: Mutations in CDKN2A impact two major anti-proliferative axes (RB and p53 pathways) and are found in a substantial fraction of various cancers.
Clinical note for exams: For p16 (INK4A) you should know it inhibits RB pathway; for ARF you should know it stabilizes p53 by antagonizing MDM2.
Additional nuance: In some tumors, RB and p53 may each be compromised independently; the presence of both mutated can be redundant but also synergistic in driving progression.
BRCA1/BRCA2: The Caretaker Tumor Suppressors (DNA Repair Gatekeepers)
BRCA1 and BRCA2 are caretaker tumor suppressors: they maintain genome stability by repairing DNA double-strand breaks (DSBs) via homologous recombination (HR).
DNA damage response sequence (simplified):
Ionizing radiation or other sources cause DSBs.
ATM kinase is activated by DSBs, then activates p53 and participates in DNA repair signaling.
ATM also interacts with BRCA1 and DNA end resection machinery (exonuclease complex) to create single-stranded DNA ends.
BRCA2 and RAD51 assemble at single-stranded regions to promote strand invasion and use the sister chromatid as the template for error-free repair by HR.
BRCA1/BRCA2 are distinct from gatekeepers in that they primarily promote accurate DNA repair rather than directly regulating cell cycle checkpoints; their loss increases mutation rate, contributing to genomic instability.
ATM may be considered both a gatekeeper and caretaker in some contexts because it coordinates damage detection and repair and can influence apoptosis.
Consequence: Defects in BRCA1/BRCA2 lead to reliance on alternative, error-prone repair pathways, contributing to mutagenesis and cancer progression.
Other Key Tumor Suppressors and Pathway Interactions
PTEN: a major tumor suppressor that negatively regulates the AKT pathway. Loss of PTEN function leads to AKT activation and promotes cell survival and growth.
p53: a central tumor suppressor; regulates RB, p21, and apoptosis; loss or mutation of p53 disrupts multiple antiproliferative and pro-apoptotic responses.
RB (retinoblastoma) pathway: governs cell cycle progression; phosphorylation state controls entry into S-phase.
ATM: DNA damage sensor; activates p53 and BRCA1/2 pathways; contributes to DNA damage response and apoptosis.
The network is highly interconnected: p53 can activate p21, which inhibits CDKs, reducing RB phosphorylation; RB activity blocks cell cycle progression; BRCA1/BRCA2 cooperate with ATM to repair DNA and maintain genomic integrity.
Takeaway: Many tumor suppressors influence more than one downstream pathway; redundancy means that inactivating several nodes can be necessary for full transformation.
The Role of BRCA as a Caretaker Versus Gatekeeper (Revisited)
BRCA1/BRCA2 are caretaker genes because they regulate DNA repair and genome stability rather than directly controlling cell cycle decisions.
Unlike gatekeepers that directly inhibit proliferation (e.g., by blocking CDKs), caretaker defects increase mutagenesis rather than triggering an immediate proliferation signal.
Implication for therapeutics and screening:
Caretaker defects are excellent markers for inherited cancer risk and screening strategies (e.g., BRCA mutations signaling higher risk).
They are not straightforward therapeutic targets because restoring BRCA function in already-established cancers is challenging and may not reverse established mutations.
Important nuance from class discussion: restoring BRCA function in BRCA-mutant cancers is unlikely to be a practical therapeutic strategy because the cancer already harbors multiple mutations; the core value of BRCA defects is increased mutational burden, not a direct driver of proliferation.
Epigenetics in Cancer: Beyond DNA Sequence Changes
Not all cancer alterations are due to DNA sequence mutations; epigenetic changes can regulate gene expression without altering the nucleotide sequence.
Epigenetic mechanisms include:
DNA methylation of CpG dinucleotides: often methylated CpGs in promoters correlate with gene silencing; demethylation can activate gene expression.
Histone modifications: methylation, acetylation states affect chromatin accessibility and gene expression; analysis often requires chromatin immunoprecipitation rather than simple sequencing.
CpG methylation patterns: maintenance methylation by methyltransferases; hypermethylation at promoters silences tumor suppressor genes; hypomethylation can activate genes and contribute to oncogenesis; methylation patterns can exist in normal tissue early in cancer progression.
Diagnostic approaches: methylation patterns can be assessed by restriction enzymes sensitive to methylation to identify hyper- or hypomethylation in cancer-related genes.
Epigenetic changes can be compared to mutations using DNA microarrays to study RNA expression differences; differences without sequence changes suggest epigenetic regulation.
Colon cancer progression and epigenetics: epigenetic alterations can accompany or precede genetic mutations and may influence the order of mutational events or create permissive states for tumor progression.
DNA Microarrays and Expression Profiling in Cancer
DNA microarrays enable high-throughput assessment of gene expression differences between tumor and normal tissue.
Basic workflow (as described):
Isolate RNA from tumor and normal tissue.
Convert RNA to cDNA and label with fluorescent dyes (e.g., green for normal, red for tumor).
Hybridize labeled cDNA to a microarray containing thousands of gene sequences.
Read spots: green indicates higher expression in normal tissue, red indicates higher expression in tumor tissue, yellow indicates similar expression in both.
Interpretation: stronger red spots suggest oncogene upregulation in cancer; stronger green spots suggest tumor suppressor gene upregulation in normal tissue (though not always the case).
Purpose: identify patterns of coordinately regulated genes that may reflect chromatin state changes or epigenetic regulation; followed by sequencing to determine whether changes are due to mutations or epigenetic control.
Practical notes: microarrays can cover many genes (e.g., all known oncogenes, or metabolism genes) with multiple probes per gene to ensure coverage.
Colorectal Cancer: A Model of Stepwise Mutations and Order of Events
Common, well-characterized pathway with a typical order of mutations and tumor progression: 1) APC mutation → activation of β-catenin signaling → early adenomas (small polyps).
APC is a regulator of the β-catenin pathway; its mutation promotes proliferation.
2) KRAS mutation → progression from early to intermediate adenomas.
3) SMAD4 mutation → defect in transforming growth factor-β signaling → progression to later adenomas.
4) TP53 mutation → transition to carcinoma.
Rationale for ordered mutations: early proliferative mutations may be clamped by normal regulation; only when a sequence of mutations accumulates (in the right order) can the cell overcome apoptosis and other barriers, allowing malignant transformation.
Genetic instability: accumulates ongoing mutations; additional mutations drive invasion and metastasis.
Takeaway: while many cancers feature multiple mutations, colon cancer often follows a characteristic sequence, highlighting the importance of the order of mutational events for full transformation.
Therapeutic Implications and Strategies: Targeting Hallmarks of Cancer
Core idea: understanding the hallmarks and their molecular underpinnings informs targeted therapeutic strategies; multi-pronged approaches may be necessary to address cancer heterogeneity.
Oncogene targeting (direct inhibitors):
If an oncogene is activated, direct inhibitors or disruption of essential downstream interactions can suppress the cancer-driving signal.
Approaches include small-molecule inhibitors and disruption of key protein–protein interactions; drug discovery can use structure-based design or high-throughput screening.
Tumor suppressor pathways and the challenge of reactivating lost function:
Reactivating a mutated tumor suppressor like p53 is difficult if the gene is deleted or severely mutated.
Alternative strategies include targeting downstream effectors (e.g., CDK inhibitors to compensate when p53/p21 axis is compromised) or activating redundant tumor-suppressor pathways that can induce p21 or other CDK inhibitors via different signaling routes (e.g., TGF-β pathway).
Therapeutic concepts discussed:
Directly inhibiting cyclin-dependent kinases (CDKs) to counteract loss of endogenous CDK inhibitors (e.g., p21).
Exploiting redundancy by activating alternative pathways that converge on the same tumor-suppressive outputs (e.g., enhancing TGF-β signaling to induce CDK inhibitors).
Targeting downstream nodes of tumor suppressors (e.g., AKT inhibitors if PTEN is lost).
Caretaker gene targets and limitations:
BRCA1/BRCA2 defects increase mutational burden rather than providing a direct proliferative signal; restoring BRCA function in established cancers is generally not practical as a therapeutic strategy because the mutational landscape is already set.
Caretaker mutations are valuable for risk assessment and prevention strategies (screening) but not straightforward therapeutic targets.
Telomere maintenance and angiogenesis as strategic targets:
Telomerase inhibitors may limit immortalization, potentially affecting cancers irrespective of other mutations.
Anti-angiogenic therapies can stall tumor growth by cutting off the blood supply, limiting tumor growth and metastasis even if proliferative signals persist.
Immunotherapy and combination approaches:
Integrating targeted pathway inhibition with immunotherapy holds promise for more effective treatment.
Combination strategies that hit multiple hallmarks simultaneously may yield better outcomes than single-agent therapies.
Personalized medicine and diagnostics:
Advances in tumor and normal tissue sequencing or microarrays enable rapid profiling of mutations and expression patterns.
The goal is to design a tailored therapeutic cocktail that targets the specific dysregulated pathways in a patient’s tumor while considering normal tissue biology.
Practical outlook: sequencing and expression profiling could guide therapy selection, with adjustments based on response.
Clinical reasoning on targetability:
Inhibitors of CDKs (e.g., CDK4/6 inhibitors) are a major focus due to their central role in cell cycle progression and their regulation by p53/p21 and RB.
If a tumor’s p53 pathway is compromised, reliance on CDK inhibitors or activation of alternative tumor-suppressor pathways becomes a pragmatic strategy.
Some tumor suppressors may present no easy therapeutic targets because they control genome integrity rather than a targetable downstream signal; in such cases, prevention and screening are more effective than treatment.
Final exam and course takeaway:
No two cancers have identical mutation profiles; the clinical objective is to disrupt multiple hallmarks in a patient-specific manner.
Therapeutic strategies should consider pathway redundancy, the stage of cancer progression, and whether a target is upstream (driver) or downstream (supporting) of essential growth processes.
Synthesis: Key Takeaways for Exam Preparation
Know the major tumor suppressor pathways and their primary targets:
p53 pathway (p53 → p21; p21 inhibits CDKs; RB remains active; cell cycle arrest)
RB pathway (CDK–cyclin activity phosphorylates RB to promote cell cycle progression; CDK inhibitors like p16^INK4a can block this)
PTEN–AKT axis (PTEN loss → AKT activation → survival/growth)
TGF-β/SMAD signaling (inhibitory signal; mutations lead to loss of growth inhibition; downstream CDK inhibitors like p21)
Understand the dual outputs of CDKN2A (p16 and ARF) and their distinct mechanisms:
p16 inhibits CDK4/6; ARF stabilizes p53 by antagonizing MDM2.
Distinguish gatekeepers and caretakers:
Gatekeepers directly regulate cell proliferation (e.g., RB, p53, PTEN in some contexts).
Caretakers (BRCA1/BRCA2) maintain genome integrity by DNA repair; their loss increases mutational load but does not directly drive proliferation.
Grasp the colorectal cancer progression model with a typical mutation order and why order matters.
Be able to describe how epigenetic changes and DNA methylation can contribute to cancer, including how CpG methylation status correlates with gene expression and how methylation patterns may serve as biomarkers.
Know how DNA microarrays work and how expression data can hint at oncogene activation or tumor suppressor loss.
Appreciate therapeutic strategies emerging from this biology: direct oncogene inhibition, CDK inhibitors, activation of alternative tumor-suppressor pathways, exploitation of epigenetic mechanisms, telomerase inhibitors, anti-angiogenic therapy, and immunotherapy; recognize the role of personalized medicine in choosing targeted therapies.
Recognize the practical limitations and the concept that stopping cancer may require only partial pathway disruption rather than fixing every mutated gene; telomerase inhibition or anti-angiogenic therapy can help contain tumor growth even when other pathways remain dysregulated.
Quick References and Notation (for Review)
Oncogenes and tumor suppressors:
Oncogene activation: growth-promoting signals persistently active.
Tumor suppressor inactivation: loss of inhibitory controls on the cell cycle.
Core signaling axis (p53–p21–CDK–RB):
CDKN2A products:
inhibits –cyclin activity, keeping RB hypophosphorylated.
binds , preventing p53 degradation, increasing p53 activity.
BRCA1/BRCA2 and HR repair:
DSBs → ATM activation → BRCA1/BRCA2–RAD51–dependent homologous recombination repair.
Colorectal cancer mutation order (typical):
APC
ightarrow eta ext{-catenin activation}
ightarrow ext{early adenoma}
Epigenetics concepts:
DNA methylation patterns at CpG dinucleotides influence gene expression; hypermethylation often silences tumor suppressor genes, hypomethylation can activate gene expression or genomic instability.
DNA microarray readouts:
Red spots indicate higher expression in cancer; green spots higher in normal; yellow indicates equal expression.
Title for the Notes
Notes on Tumor Suppressors, Oncogenes, Epigenetics, and Therapeutic Implications